Please click on the ID to see detailed information about each entry.
The total number entries retrieved from this search are| ID | Sequence | Name | Nature of peptide or cargo | Assay | Tissue permeability | Tissue Sample | PUBMED ID |
|---|---|---|---|---|---|---|---|
| 1259 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Algesic response: ~15(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. Maximal painful response was attained 1-2 minutes after drug administration and faded after 5 minutes. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1260 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Algesic response: ~22(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. Maximal painful response was attained 1-2 minutes after drug administration and faded after 5 minutes. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1261 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin vehicle pretreatment: ~15.3(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1265 | SNLST-Asu-VLGKLSQELH KLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | Calcium C-Test Wako kit, Ames method, Alkaline Phospha K-Test and ANOVA | Parameters studied: Ca(mg/dl)- 8.83±0.20/8.94±0.17(control), P(mg/dl)- 5.32±0.35/5.58±0.55(control) and Alkaline phosphatase- 23.69±1.16/18.83±0.75(control) | Abdominal skin of female wistar rats | 8268857 |
| 1266 | SNLST-Asu-VLGKLSQELH KLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | Calcium C-Test Wako kit, Ames method, Alkaline Phospha K-Test and ANOVA | Parameters studied: Ca(mg/dl)- 8.80±0.27/8.94±0.17(control), P(mg/dl)- 5.22±0.36/5.58±0.55(control) and Alkaline phosphatase- 22.21±4.01/18.83±0.75(control) | Abdominal skin of female wistar rats | 8268857 |
| 1267 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of number of cups | Measurement of number of cups: Control:1.5 , Test:3 | In castrated testosterone treated rats | 8156912 |
| 1268 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of number of cups | Measurement of number of cups: Control:4 , Test:9 | In castrated testosterone treated rats | 8156912 |
| 1269 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of number of cups | Measurement of number of cups: Control:4.5 , Test:7.5 | In castrated testosterone treated rats | 8156912 |
| 1270 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of number of cups | Measurement of number of cups: Control:7 , Test:15 | In castrated testosterone treated rats | 8156912 |
| 1271 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of E2(Erection) | Measurement of E2(Erection): Control:15 , Test:26 | In castrated testosterone treated rats | 8156912 |
| 1272 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of E2(Erection) | Measurement of E2(Erection): Control:4 , Test:11 | In castrated testosterone treated rats | 8156912 |
| 1273 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of E2(Erection) | Measurement of E2(Erection): Control:6 , Test:12 | In castrated testosterone treated rats | 8156912 |
| 1274 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of E2(Erection) | Measurement of E2(Erection): Control:11 , Test:24 | In castrated testosterone treated rats | 8156912 |
| 1275 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first cup | Measurement of latency of first cup: Control:44 minutes , Test:38 minutes | In castrated testosterone treated rats | 8156912 |
| 1276 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first cup | Measurement of latency of first cup: Control:25.5 minutes , Test:19 minutes | In castrated testosterone treated rats | 8156912 |
| 1277 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first cup | Measurement of latency of first cup: Control:39 minutes , Test:32 minutes | In castrated testosterone treated rats | 8156912 |
| 1278 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first cup | Measurement of latency of first cup: Control:23 minutes , Test:15 minutes | In castrated testosterone treated rats | 8156912 |
| 1279 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first E2(Erection) | Measurement of latency of first E2(Erection): Control:29 minutes , Test:31 minutes | In castrated testosterone treated rats | 8156912 |
| 1280 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first E2(Erection) | Measurement of latency of first E2(Erection): Control:32 minutes , Test:16 minutes | In castrated testosterone treated rats | 8156912 |
| 1281 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first E2(Erection) | Measurement of latency of first E2(Erection): Control:9 minutes , Test:3 minutes | In castrated testosterone treated rats | 8156912 |
| 1282 | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Stearyl-VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first E2(Erection) | Measurement of latency of first E2(Erection): Control:3.5 minutes , Test:2 minutes | In castrated testosterone treated rats | 8156912 |
| 1283 | HSDAVFTDNYTRLR KQ-Nle-AVKKYLNSILN | Stearyl-Nle17- VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of number of cups | Measurement of number of first cup: Control:7 minutes , Test:20.2 minutes | In castrated testosterone treated rats | 8156912 |
| 1284 | HSDAVFTDNYTRLR KQ-Nle-AVKKYLNSILN | Stearyl-Nle17- VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of E2(Erection) | Measurement of number of first E2(Erection): Control:11 minutes , Test:35 minutes | In castrated testosterone treated rats | 8156912 |
| 1285 | HSDAVFTDNYTRLR KQ-Nle-AVKKYLNSILN | Stearyl-Nle17- VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first cup | Measurement of latency of first cup: Control:23 minutes , Test:10 minutes | In castrated testosterone treated rats | 8156912 |
| 1286 | HSDAVFTDNYTRLR KQ-Nle-AVKKYLNSILN | Stearyl-Nle17- VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay, Measurement of latency of first E2(Erection) | Measurement of latency of first E2(Erection): Control:3.5 minutes , Test:1.9 minutes | In castrated testosterone treated rats | 8156912 |
| 1287 | HSDAVFTDNYTRLR KQ-Nle-AVKKYLNSILN | Stearyl-Nle17- VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay | Time course of distribution of radioactively labelled peptide: Control:6 minutes , Test:20 minutes | Three-month-old diabetic rats | 8156912 |
| 1288 | HSDAVFTDNYTRLR KQ-Nle-AVKKYLNSILN | Stearyl-Nle17- VIP | A key penile neurotransmitter, induces erection after local injection in man. Significantly increased sexual function as measured by copulatory activity and penile reflexes(erections) in testosterone-treated, castrated rats. | Radioactive assay | Time course of distribution of radioactively labelled peptide:Control:5.5 minutes , Test:21.5 minutes | Spontaneous high blood pressure rats(SHR) | 8156912 |
| 1289 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 57% (32 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1290 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 55% (23 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1291 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 54% (21 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1292 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 56% (20 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1293 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 58% (16 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1294 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 61% (14 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1325 | YGGFL | Leu-enkephalin | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 0.01% GFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1326 | YGGFL | Leu-enkephalin | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 0.03% GGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1327 | YGGFL | Leu-enkephalin | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 0.035% FL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1328 | YGGFL | Leu-enkephalin | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 0.1% YGGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1329 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 1% aGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1330 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 18.5% YaGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1331 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 3.75% aGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1332 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 10.75% YaGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1333 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7)-a-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone, a-MSH, in several bioassays | Frog Skin Bioassay | Head and neck(85.7%), Trunk(8.7%),Leg(25%) | Stratum corneum of human skin samples (obtained from freshly excised surgical specimens) | 2155969 |
| 1334 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7)-a-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone, a-MSH, in several bioassays | Radioimmunoassay | Head and neck(78.6%), Trunk(8.8%),Leg(33.3%) | Stratum corneum of human skin samples (obtained from freshly excised surgical specimens) | 2155969 |
| 1335 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=30.99±11.75 , Area under the first moment curve(mg.h2/dl)=371.41±159.80 , The mean residence time(h)=12.06±1.99 , Apparent bioavailability(%)=2.68. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |
| 1336 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=46.25±19.25 , Area under the first moment curve(mg.h2/dl)=623.71±233.74 , The mean residence time(h)=13.81±2.36 , Apparent bioavailability(%)=3.99. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |
| 1337 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=36.13±21.93 , Area under the first moment curve(mg.h2/dl)=445.49±248.06 , The mean residence time(h)=12.83±1.68 , Apparent bioavailability(%)=3.12. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |
| 1338 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=17.25±10.07 , Area under the first moment curve(mg.h2/dl)=271.52±106.34 , The mean residence time(h)=18.16±6.19 , Apparent bioavailability(%)=1.49. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |
| 1339 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=53.50±14.96 , Area under the first moment curve(mg.h2/dl)=752.04±298.40 , The mean residence time(h)=13.66±3.46 , Apparent bioavailability(%)=4.62. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |
| 1340 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=31.97±17.89 , Area under the first moment curve(mg.h2/dl)=505.37±238.24 , The mean residence time(h)=16.32±2.35 , Apparent bioavailability(%)=2.76. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |
| 1341 | SNLST-Asu-VLGKLSQEL HKLQTYPRTDVGAGTP | Elcatonin | It stimulates osteoblastic bone formation in addition to inhibiting osteoclastic bone resorption | o-cresolphthalein complexone method using Calcium C-Test Wako and 0.01 ml plasma, pharmacokinetic and statistical analysis | Area under the curve(mg.h/dl)=40.85±20.01 , Area under the first moment curve(mg.h2/dl)=513.32±292.53 , The mean residence time(h)=12.34±2.37 , Apparent bioavailability(%)=3.53. | Stratum corneum of the abdominal area of male Wistar rats(0.5g ointment/4 cm2/rat) | 2054872 |